Update on pharmacological treatment of progressive myoclonus epilepsies

Edoardo Ferlazzo, Dorothee Kasteleijn Nolst Trenite, Gerrit Jan de Haan, Felix Nitschke, Saija Ahonen, Sara Gasparini, Berge A. Minassian

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Progressive myoclonus epilepsies (PMEs) are a group of rare inherited diseases featuring a combination of myoclonus, seizures and variable degree of cognitive impairment. Despite extensive investigations, a large number of PMEs remain undiagnosed. In this review, we focus on the current pharmacological approach to PMEs. Methods: References were mainly identified through PubMed search until February 2017 and backtracking of references in pertinent studies. Results: The majority of available data on the efficacy of antiepileptic medications in PMEs are primarily anecdotal or observational, based on individual responses in small series. Valproic acid is the drug of choice, except for PMEs due to mitochondrial diseases. Levetiracetam and clonazepam should be considered as the first add-on treatment. Zonisamide and perampanel represent promising alternatives. Phenobarbital and primidone should be reserved to patients with resistant disabling myoclonus or seizures. Lamotrigine should be used with caution due to its unpredictable effect on myoclonus. Avoidance of drugs known to aggravate myoclonus and seizures, such as carbamazepine and phenytoin, is paramount. Psychiatric (in particular depression) and other comorbidities need to be adequately managed. Although a 3- to 4-drug regimen is often necessary to control seizures and myoclonus, particular care should be paid to avoid excessive pharmacological load and neurotoxic side effects. Target therapy is possible only for a minority of PMEs. Conclusions: Overall, the treatment of PMEs remains symptomatic (i.e. pharmacological treatment of seizures and myoclonus). Further dissection of the genetic background of the different PMEs might hopefully help in the future with individualised treatment options.

Original languageEnglish (US)
Pages (from-to)5662-5666
Number of pages5
JournalCurrent Pharmaceutical Design
Volume23
Issue number37
DOIs
StatePublished - Jan 1 2017

Fingerprint

Progressive Myoclonic Epilepsy
Myoclonus
Pharmacology
Seizures
zonisamide
etiracetam
Therapeutics
Primidone
Pharmaceutical Preparations
Clonazepam
Mitochondrial Diseases
Carbamazepine
Valproic Acid
Phenytoin
Phenobarbital
Rare Diseases
PubMed
Anticonvulsants
Psychiatry
Dissection

Keywords

  • Antiepileptic drugs
  • Epilepsy
  • Myoclonic jerks
  • Photoparoxysmal response
  • Seizures
  • Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Ferlazzo, E., Trenite, D. K. N., de Haan, G. J., Nitschke, F., Ahonen, S., Gasparini, S., & Minassian, B. A. (2017). Update on pharmacological treatment of progressive myoclonus epilepsies. Current Pharmaceutical Design, 23(37), 5662-5666. https://doi.org/10.2174/1381612823666170809114654

Update on pharmacological treatment of progressive myoclonus epilepsies. / Ferlazzo, Edoardo; Trenite, Dorothee Kasteleijn Nolst; de Haan, Gerrit Jan; Nitschke, Felix; Ahonen, Saija; Gasparini, Sara; Minassian, Berge A.

In: Current Pharmaceutical Design, Vol. 23, No. 37, 01.01.2017, p. 5662-5666.

Research output: Contribution to journalReview article

Ferlazzo, E, Trenite, DKN, de Haan, GJ, Nitschke, F, Ahonen, S, Gasparini, S & Minassian, BA 2017, 'Update on pharmacological treatment of progressive myoclonus epilepsies', Current Pharmaceutical Design, vol. 23, no. 37, pp. 5662-5666. https://doi.org/10.2174/1381612823666170809114654
Ferlazzo E, Trenite DKN, de Haan GJ, Nitschke F, Ahonen S, Gasparini S et al. Update on pharmacological treatment of progressive myoclonus epilepsies. Current Pharmaceutical Design. 2017 Jan 1;23(37):5662-5666. https://doi.org/10.2174/1381612823666170809114654
Ferlazzo, Edoardo ; Trenite, Dorothee Kasteleijn Nolst ; de Haan, Gerrit Jan ; Nitschke, Felix ; Ahonen, Saija ; Gasparini, Sara ; Minassian, Berge A. / Update on pharmacological treatment of progressive myoclonus epilepsies. In: Current Pharmaceutical Design. 2017 ; Vol. 23, No. 37. pp. 5662-5666.
@article{8f57386eed5b4cf0b1253450be0d7728,
title = "Update on pharmacological treatment of progressive myoclonus epilepsies",
abstract = "Background: Progressive myoclonus epilepsies (PMEs) are a group of rare inherited diseases featuring a combination of myoclonus, seizures and variable degree of cognitive impairment. Despite extensive investigations, a large number of PMEs remain undiagnosed. In this review, we focus on the current pharmacological approach to PMEs. Methods: References were mainly identified through PubMed search until February 2017 and backtracking of references in pertinent studies. Results: The majority of available data on the efficacy of antiepileptic medications in PMEs are primarily anecdotal or observational, based on individual responses in small series. Valproic acid is the drug of choice, except for PMEs due to mitochondrial diseases. Levetiracetam and clonazepam should be considered as the first add-on treatment. Zonisamide and perampanel represent promising alternatives. Phenobarbital and primidone should be reserved to patients with resistant disabling myoclonus or seizures. Lamotrigine should be used with caution due to its unpredictable effect on myoclonus. Avoidance of drugs known to aggravate myoclonus and seizures, such as carbamazepine and phenytoin, is paramount. Psychiatric (in particular depression) and other comorbidities need to be adequately managed. Although a 3- to 4-drug regimen is often necessary to control seizures and myoclonus, particular care should be paid to avoid excessive pharmacological load and neurotoxic side effects. Target therapy is possible only for a minority of PMEs. Conclusions: Overall, the treatment of PMEs remains symptomatic (i.e. pharmacological treatment of seizures and myoclonus). Further dissection of the genetic background of the different PMEs might hopefully help in the future with individualised treatment options.",
keywords = "Antiepileptic drugs, Epilepsy, Myoclonic jerks, Photoparoxysmal response, Seizures, Therapy",
author = "Edoardo Ferlazzo and Trenite, {Dorothee Kasteleijn Nolst} and {de Haan}, {Gerrit Jan} and Felix Nitschke and Saija Ahonen and Sara Gasparini and Minassian, {Berge A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1381612823666170809114654",
language = "English (US)",
volume = "23",
pages = "5662--5666",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "37",

}

TY - JOUR

T1 - Update on pharmacological treatment of progressive myoclonus epilepsies

AU - Ferlazzo, Edoardo

AU - Trenite, Dorothee Kasteleijn Nolst

AU - de Haan, Gerrit Jan

AU - Nitschke, Felix

AU - Ahonen, Saija

AU - Gasparini, Sara

AU - Minassian, Berge A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Progressive myoclonus epilepsies (PMEs) are a group of rare inherited diseases featuring a combination of myoclonus, seizures and variable degree of cognitive impairment. Despite extensive investigations, a large number of PMEs remain undiagnosed. In this review, we focus on the current pharmacological approach to PMEs. Methods: References were mainly identified through PubMed search until February 2017 and backtracking of references in pertinent studies. Results: The majority of available data on the efficacy of antiepileptic medications in PMEs are primarily anecdotal or observational, based on individual responses in small series. Valproic acid is the drug of choice, except for PMEs due to mitochondrial diseases. Levetiracetam and clonazepam should be considered as the first add-on treatment. Zonisamide and perampanel represent promising alternatives. Phenobarbital and primidone should be reserved to patients with resistant disabling myoclonus or seizures. Lamotrigine should be used with caution due to its unpredictable effect on myoclonus. Avoidance of drugs known to aggravate myoclonus and seizures, such as carbamazepine and phenytoin, is paramount. Psychiatric (in particular depression) and other comorbidities need to be adequately managed. Although a 3- to 4-drug regimen is often necessary to control seizures and myoclonus, particular care should be paid to avoid excessive pharmacological load and neurotoxic side effects. Target therapy is possible only for a minority of PMEs. Conclusions: Overall, the treatment of PMEs remains symptomatic (i.e. pharmacological treatment of seizures and myoclonus). Further dissection of the genetic background of the different PMEs might hopefully help in the future with individualised treatment options.

AB - Background: Progressive myoclonus epilepsies (PMEs) are a group of rare inherited diseases featuring a combination of myoclonus, seizures and variable degree of cognitive impairment. Despite extensive investigations, a large number of PMEs remain undiagnosed. In this review, we focus on the current pharmacological approach to PMEs. Methods: References were mainly identified through PubMed search until February 2017 and backtracking of references in pertinent studies. Results: The majority of available data on the efficacy of antiepileptic medications in PMEs are primarily anecdotal or observational, based on individual responses in small series. Valproic acid is the drug of choice, except for PMEs due to mitochondrial diseases. Levetiracetam and clonazepam should be considered as the first add-on treatment. Zonisamide and perampanel represent promising alternatives. Phenobarbital and primidone should be reserved to patients with resistant disabling myoclonus or seizures. Lamotrigine should be used with caution due to its unpredictable effect on myoclonus. Avoidance of drugs known to aggravate myoclonus and seizures, such as carbamazepine and phenytoin, is paramount. Psychiatric (in particular depression) and other comorbidities need to be adequately managed. Although a 3- to 4-drug regimen is often necessary to control seizures and myoclonus, particular care should be paid to avoid excessive pharmacological load and neurotoxic side effects. Target therapy is possible only for a minority of PMEs. Conclusions: Overall, the treatment of PMEs remains symptomatic (i.e. pharmacological treatment of seizures and myoclonus). Further dissection of the genetic background of the different PMEs might hopefully help in the future with individualised treatment options.

KW - Antiepileptic drugs

KW - Epilepsy

KW - Myoclonic jerks

KW - Photoparoxysmal response

KW - Seizures

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85042511514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042511514&partnerID=8YFLogxK

U2 - 10.2174/1381612823666170809114654

DO - 10.2174/1381612823666170809114654

M3 - Review article

VL - 23

SP - 5662

EP - 5666

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 37

ER -